These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 31094258)
1. Poly Lactic-co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy. Kohnepoushi C; Nejati V; Delirezh N; Biparva P Immunol Invest; 2019 Nov; 48(8):794-808. PubMed ID: 31094258 [TBL] [Abstract][Full Text] [Related]
2. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens. Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834 [TBL] [Abstract][Full Text] [Related]
3. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Hanlon DJ; Aldo PB; Devine L; Alvero AB; Engberg AK; Edelson R; Mor G Am J Reprod Immunol; 2011 Jun; 65(6):597-609. PubMed ID: 21241402 [TBL] [Abstract][Full Text] [Related]
4. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918 [TBL] [Abstract][Full Text] [Related]
5. Mannosylated polylactic-co-glycolic acid (MN-PLGA) nanoparticles induce potent anti-tumor immunity in murine model of breast cancer. Sheikhzadeh S; Delirezh N; Hobbenaghi R Biomed Pharmacother; 2021 Oct; 142():111962. PubMed ID: 34358752 [TBL] [Abstract][Full Text] [Related]
6. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells. Heo MB; Cho MY; Lim YT Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635 [TBL] [Abstract][Full Text] [Related]
8. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4 Tang XD; Lü KL; Yu J; Du HJ; Fan CQ; Chen L Cancer Immunol Immunother; 2022 Dec; 71(12):2969-2983. PubMed ID: 35546204 [TBL] [Abstract][Full Text] [Related]
10. Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles. Prasad S; Cody V; Saucier-Sawyer JK; Fadel TR; Edelson RL; Birchall MA; Hanlon DJ Pharm Res; 2012 Sep; 29(9):2565-77. PubMed ID: 22798259 [TBL] [Abstract][Full Text] [Related]
11. Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. Kokate RA; Chaudhary P; Sun X; Thamake SI; Maji S; Chib R; Vishwanatha JK; Jones HP Nanomedicine (Lond); 2016; 11(5):479-94. PubMed ID: 26892440 [TBL] [Abstract][Full Text] [Related]
12. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Heo MB; Kim SY; Yun WS; Lim YT Int J Nanomedicine; 2015; 10():5981-92. PubMed ID: 26451105 [TBL] [Abstract][Full Text] [Related]
13. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. Ma W; Smith T; Bogin V; Zhang Y; Ozkan C; Ozkan M; Hayden M; Schroter S; Carrier E; Messmer D; Kumar V; Minev B J Transl Med; 2011 Mar; 9():34. PubMed ID: 21450109 [TBL] [Abstract][Full Text] [Related]
14. Immunotoxicity of poly (lactic-co-glycolic acid) nanoparticles: influence of surface properties on dendritic cell activation. Barillet S; Fattal E; Mura S; Tsapis N; Pallardy M; Hillaireau H; Kerdine-Römer S Nanotoxicology; 2019 Jun; 13(5):606-622. PubMed ID: 30760076 [TBL] [Abstract][Full Text] [Related]
15. Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate. Bae WK; Umeyama A; Chung IJ; Lee JJ; Takei M Cell Immunol; 2010; 266(1):104-10. PubMed ID: 20933226 [TBL] [Abstract][Full Text] [Related]
17. In vitro induction of specific anti-tumoral immunity against laryngeal carcinoma by using human interleukin-12 gene-transfected dendritic cells. Liang W; Wang XF Chin Med J (Engl); 2011 May; 124(9):1357-61. PubMed ID: 21740748 [TBL] [Abstract][Full Text] [Related]
18. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles. Rosalia RA; Silva AL; Camps M; Allam A; Jiskoot W; van der Burg SH; Ossendorp F; Oostendorp J Cancer Immunol Immunother; 2013 Jul; 62(7):1161-73. PubMed ID: 23613147 [TBL] [Abstract][Full Text] [Related]
19. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703 [TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]